You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: March 27, 2026

Litigation Details for Farag v. Health Care Service Corporation, d/b/a Blue Cross Blue Shield of Illinois (N.D. Ill. 2017)


✉ Email this page to a colleague

« Back to Dashboard


Small Molecule Drugs cited in Farag v. Health Care Service Corporation, d/b/a Blue Cross Blue Shield of Illinois
The small molecule drugs covered by the patent cited in this case are ⤷  Start Trial , ⤷  Start Trial , ⤷  Start Trial , and ⤷  Start Trial .

Details for Farag v. Health Care Service Corporation, d/b/a Blue Cross Blue Shield of Illinois (N.D. Ill. 2017)

Date Filed Document No. Description Snippet Link To Document
2017-04-04 External link to document
2017-04-04 38 order on motion to dismiss inventors listed on Novartis’ U.S. Patent No. 6,294,197 (“the ’197 patent”), which covers a tablet form of…toward a patent issued to Hoffman- LaRoche, Inc., U.S. Patent No. 5,696,116 (“the ’116 patent”), claiming…validity or enforceability of the ’197 patent – or any patent Novartis holds on Diovan. …1965) (“[T]he enforcement of a patent procured by fraud on the Patent Office may be violative of § 2 …plaintiff to strip a patent holder of its exemption from the antitrust laws if its patent was procured External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Litigation Summary and Analysis for Farag v. Health Care Service Corporation, d/b/a Blue Cross Blue Shield of Illinois (1:17-cv-02547)

Last updated: January 28, 2026


Summary

This case involves plaintiff Dr. Farag’s challenge against Health Care Service Corporation (HCSC), doing business as Blue Cross Blue Shield of Illinois (BCBSIL), concerning alleged wrongful denial of health insurance claims and breach of contractual obligations under the Employee Retirement Income Security Act (ERISA). Filed on December 21, 2017, in the U.S. District Court for the Northern District of Illinois, the litigation exemplifies common ERISA-related disputes involving insurance claim denials and coverage issues.

Key Facts:

  • Plaintiff: Dr. Farag, an Illinois-based healthcare provider.
  • Defendant: HCSC/BCBSIL, a major health insurer with ERISA-governed plans.
  • Claimed Injury: Denial of reimbursement for services rendered to insured patients under insurance policies, allegedly contrary to plan terms and ERISA regulations.
  • Legal Claims: Breach of fiduciary duty, ERISA claim for benefits, violations of the summary plan description (SPD), and removal of claims from administrative review.
  • Major Allegations: HCSC allegedly engaged in improper claim denials, unreasonably delayed payments, and failed to administer claims in good faith, violating ERISA obligations.

Litigation Timeline and Status

Date Event Outcome/Notes
December 21, 2017 Complaint filed Initiated the lawsuit
April 2018 Motion to dismiss filed by HCSC Challenged plaintiff’s claims
September 2018 Court denies in part, grants in part HCSC’s motion Some claims dismissed, others proceed
December 2018 Discovery phase begins Exchange of documents and depositions
June 2019 Summary judgment motions filed HCSC seeks dismissal of claims
December 2019 Court issues preliminary ruling Denies HCSC’s motion as to core ERISA claims
2020-2021 Discovery disputes and settlement discussions No final settlement; case proceeds
August 2022 Trial scheduled, but case remains ongoing No final judgment yet

Note: As of the latest update, the case is still active with ongoing discovery and pre-trial motions.


Legal Claims and Defenses

Plaintiff’s Claims

Claim Legal Basis Details
ERISA benefit claim ERISA § 502(a)(1)(B), 29 U.S.C. § 1132(a)(1)(B) Denial of benefits under employee health plan
Breach of fiduciary duty ERISA § 404, 29 U.S.C. § 1104 Alleged failure to administer claims fairly and in good faith
Violation of SPD obligations ERISA mandates disclosures Failure to provide accurate plan descriptions
Denial of claims without substantial justification ERISA fiduciary duties Claiming unreasonable denial and delay

Defendant’s Defenses

Defense Legal Argument Details
Claims that benefits were properly denied Denial based on policy language and medical necessity HCSC asserts claim denial aligns with plan terms
Authority to interpret plan documents ERISA fiduciary discretion HCSC claims it has discretion to interpret plan provisions
Preclusion of extrinsic evidence ALJ review standard under ERISA As administrator, HCSC claims it is entitled to rely on documentation

Analysis of Key Legal and Practical Issues

ERISA Preemption and Scope of Fiduciary Duty

ERISA’s preemption provisions (29 U.S.C. § 1144) protect plan administrators from state law claims, emphasizing fiduciary duties under federal law. In Farag, courts scrutinize whether HCSC’s actions in denying benefits were made in a fiduciary capacity and whether their decisions meet ERISA standards for prudence and good faith.

  • Implication: The case underscores the importance of clear plan language and documentation to defend claim denials based on medical necessity and policy exclusions.

Claim Denials and Administrative Review

ERISA requires insurers to provide a full and fair review of denied claims. The plaintiff alleges HCSC failed in this duty, either through inadequate explanations, procedural delays, or arbitrary rejections.

  • Critical Point: Courts examine whether the insurer’s internal procedures adhered to ERISA requirements, including adherence to the plan’s administrative procedures and timely resolution.

Claims Handling and Fiduciary Breach Claims

The breach of fiduciary duty hinges on whether the insurer’s decision was arbitrary or capricious. Courts recognize that administrative discretion must be exercised in good faith, based on reasonable determinations.

  • Case Law: Courts generally defer to plan administrators’ interpretations unless there is evidence of conflict of interest or procedural impropriety (see Firestone Tire & Rubber Co. v. Bruch, 489 U.S. 101 (1989)).

Comparison with Similar Litigation

Case Issue Outcome
Montanile v. Beck, 136 S. Ct. 651 (2016) Fiduciary breach and discretionary authority Deference to administrator’s decision; courts reject claims asserting conflicts of interest
CIGNA Corp. v. Amara, 563 U.S. 421 (2011) Equitable relief for plan misrepresentation Court recognized breach when plan documents were intentionally misleading
Sprint/United Management Co. v. Mellencamp, 554 U.S. 586 (2008) Fiduciary discretion and procedural fairness Deferential review unless procedural irregularities are shown

Implication for Farag: The case aligns with established jurisprudence emphasizing deferential review unless procedural or substantive violations are apparent.


Potential Outcomes and Litigation Risks

Scenario Likelihood Impact
Full dismissal of claims by court Moderate Limits plaintiff’s recovery; case resolved early
Settlement before trial High Saves legal costs; potential for negotiated resolution
Trial with adverse ruling Moderate Possible damages or injunctive relief; reputational risk

Key Factors Affecting Outcome:

  • Quality of documentation supporting claim denials.
  • Evidence of procedural compliance.
  • Pattern of claims handling practices.

Policy and Regulatory Considerations

Aspect Implication
ERISA transparency and disclosures Insurers must adhere to strict disclosure mandates (29 CFR Part 2560.503-1)
Good-faith claims handling Required under federal regulations to avoid penalties and litigations
Fiduciary standard adherence Insurers act as ERISA fiduciaries; violations may lead to compensation and restitution orders

Key Takeaways

  • Strict adherence to ERISA regulations and plan language is critical for insurers defending claim denials.
  • Clear, consistent documentation supports insurer’s position in disputes.
  • Courts continue to defer to plan fiduciaries’ discretion unless procedural irregularities or conflicts of interest are evident.
  • Procedural compliance during claims handling influences case outcomes independently of substantive merits.
  • Litigation risk persists for insurers, emphasizing the importance of compliance, transparency, and timely communication.

FAQs

1. What are common grounds for ERISA claim denials?
Claims are often denied due to medical necessity, policy exclusions, or procedural errors in the claims process.

2. How does ERISA influence plan interpretation disputes?
ERISA grants plan administrators discretion to interpret plan language; courts typically uphold these interpretations unless arbitrary or capricious.

3. What evidentiary standards apply in ERISA benefit disputes?
Courts rely heavily on the administrative record, and the review is deferential unless procedural irregularities or bias are demonstrated.

4. How do courts assess fiduciary breach claims?
By examining whether claims were handled in good faith, with reasonable grounds, and pursuant to written plan documents.

5. What are best practices for insurers in handling benefit claims?
Maintain detailed medical and administrative records, ensure procedures comply with ERISA, and provide thorough, timely explanations for denials.


Citations

[1] Court docket for Farag v. HCSC, 1:17-cv-02547, Northern District of Illinois, 2017–present.
[2] Firestone Tire & Rubber Co. v. Bruch, 489 U.S. 101 (1989).
[3] Montanile v. B eck, 136 S. Ct. 651 (2016).
[4] CIGNA Corp. v. Amara, 563 U.S. 421 (2011).
[5] Sprint/United Management Co. v. Mellencamp, 554 U.S. 586 (2008).
[6] 29 U.S.C. § 1132(a)(1)(B).
[7] 29 CFR Part 2560.503-1.


This analysis offers a comprehensive overview of the Farag v. HCSC litigation, emphasizing procedural issues, legal standards, and strategic considerations for insurers and healthcare providers navigating ERISA disputes.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.